BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Sanofi (France) (SAN.PA)'s Chief Says Investors Underestimate Drug Pipeline


1/28/2013 8:22:13 AM

Sanofi (SAN) Chief Executive Officer Chris Viehbacher says investors are still underestimating the French company’s pipeline of experimental drugs. Sanofi has gained 31 percent over the past year in Paris trading, giving the company a market value of 96.4 billion euros ($129.8 billion). Sanofi last year surpassed Total SA (FP) as the biggest company by value in France’s benchmark CAC 40 (CAC) Index. “People have started to recognize the value of our diversified model, and I think the future increase is going to come from the R&D pipeline, which is underestimated,” Viehbacher said during an interview today with Bloomberg Television in Davos, Switzerland, where he is attending the World Economic Forum. Viehbacher, who became CEO in December 2008, has been bolstering Sanofi’s pipeline by reorganizing research and development, dropping the least promising projects and accelerating acquisitions and partnerships. Paris-based Sanofi needs the new products to make up for sales declines caused by generic competition to its biggest medicines, such as the Plavix blood thinner. Sanofi shares can rise further, Viehbacher said today. “There is still value in the stock,” he said. “All that we’ve done is really caught up to the rest of the industry because we clearly were at a discount. I think the whole industry is still poised for a re-rating.” Sanofi shares sell for 11.7 times this year’s estimated earnings, compared with an average price-earnings ratio of 12.7 for the world’s biggest drugmakers. Three years ago, after Viehbacher’s first year on the job, Sanofi fetched only 8.2 times earnings. Aubagio, a pill to treat multiple sclerosis, Zaltrap for cancer, and the diabetes medicine Lyxumia are among the new drugs Sanofi is bringing to market. Viehbacher has cited a vaccine against dengue, a deadly mosquito-borne virus, and a cholesterol-lowering drug targeting an enzyme called PCSK9, as experimental therapies he’s excited about.

Read at Bloomberg
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->